N/A
Manufactured by Assertio Therapeutics, Inc.
156,718 FDA adverse event reports analyzed
Last updated: 2026-04-14
DICLOFENAC POTASSIUM is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Assertio Therapeutics, Inc.. The most commonly reported adverse reactions for DICLOFENAC POTASSIUM include DRUG INEFFECTIVE, FATIGUE, RHEUMATOID ARTHRITIS, PAIN, OFF LABEL USE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for DICLOFENAC POTASSIUM.
Out of 10,021 classified reports for DICLOFENAC POTASSIUM:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 156,718 FDA FAERS reports that mention DICLOFENAC POTASSIUM. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, FATIGUE, RHEUMATOID ARTHRITIS, PAIN, OFF LABEL USE, RASH. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Assertio Therapeutics, Inc. in connection with DICLOFENAC POTASSIUM. Always verify the specific product and NDC with your pharmacist.